Real-World Data on Neovascular Age-Related Macular Degeneration: Preserving Vision Acuity While Decreasing Injection Burden of Anti-VEGF Treatments

Real-World Data on Neovascular Age-Related Macular Degeneration: Preserving Vision Acuity While Decreasing Injection Burden of Anti-VEGF Treatments

Faculty Presenters

Khalid M. Kamal, MPharm, PhD
Professor and Chair
Department of Pharmaceutical Systems and Policy
Health Sciences Center
West Virginia University School of Pharmacy
Morgantown, West Virginia

Joseph Nezgoda, MD, MBA
Managing Partner
Retina Macular Institute
West Palm Beach, Florida
 
Program Description
Neovascular age-related macular degeneration (AMD) is associated with central visual acuity loss that leads to severe visual impairment and blindness in an estimated 11 million Americans. Treatment with intravitreal anti-vascular endothelial growth factor (VEGF) agents have helped to preserve vision in many patients with neovascular AMD; however, improvements in vision preservation and quality of life come with a cost: regular, frequent office visits for monitoring, the burden of numerous intravitreal anti-VEGF injections, and financial strain for patients and caregivers. Real-world experience and outcomes with anti-VEGF agents have suggested that these barriers and burdens lead patients with AMD to receive fewer anti-VEGF injections and less frequent monitoring than guidelines recommend. Managed care professionals and pharmacists are seeing an increasing number of difficult-to-treat patients with AMD and must facilitate access to all anti-VEGF treatment options to individualize care for these patients. This activity will focus on the appropriate consideration of emerging therapies to treat neovascular AMD, factors that contribute to decreasing the disease burden, and use of best practices in cost management.  

Target audience: Managed care, payer, pharmacy benefit, pharmacy director, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional interested in the scientific advances of treating neovascular age-related macular degeneration.

Type of activity: Application
Release date: October 27, 2020
Expiration date: October 27, 2021
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

• Illustrate the epidemiology, pathophysiology, and disease burden of neovascular age-related macular degeneration (AMD)
• Examine clinical efficacy and safety, dosage regimens, and unique attributes of current and emerging anti-vascular endothelial growth factor (VEGF) agents for neovascular AMD
• Identify anti-VEGF treatment regimens to minimize the injection burden in neovascular AMD
• Explore real-world evidence in neovascular AMD

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-324-H01-P. The activity is available for CE credit through October 27, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures
Khalid Kamal, MPharm, PhD, and Joseph Nezgoda, MD, MBA, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Activity Disclaimer
Pharmacy Times Continuing Education™ (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this live CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms